Company / Working Capital
Niagen Bioscience, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$76.9M
FY2025
5-year range
$28.7M / $76.9M
FY2021-FY2025
Trend
+66.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has increased for 3 consecutive years, from $29M in FY2022 to $77M in FY2025.
Based on SEC 10-K filings.
$77M in FY2025 with a 5-year CAGR of +37.3%.
Improved from $29M to $77M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +38.9%
- 5-Year CAGR
- +37.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Niagen Bioscience, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +37.3%, indicating consistent growth.
- In FY2025, working capital increased 66.6% year-over-year.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $76.9M | +66.6% |
| FY2024 | $46.2M | +59.6% |
| FY2023 | $28.9M | +0.7% |
| FY2022 | $28.7M | -8.3% |
| FY2021 | $31.3M | +98.8% |
| FY2020 | $15.7M | -14.7% |
| FY2019 | $18.5M | -16.5% |
| FY2018 | $22.1M | -55.0% |
| FY2017 | $49.1M | +614.8% |
| FY2016 | $6.9M | -1.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026